<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39779">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588547</url>
  </required_header>
  <id_info>
    <org_study_id>SM102015</org_study_id>
    <nct_id>NCT02588547</nct_id>
  </id_info>
  <brief_title>Prevention of Spinal Induced Shivering During CS</brief_title>
  <official_title>Prophylactic Granisetron for the Prevention of Spinal Induced Shivering During Cesarean Section: a Prospective Double Blind Dose Ranging Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy of two different doses of intravenous (IV) granisetron on
      the prevention of postspinal shivering during cesarean section, in comparison with IV
      pethidine and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will includes four groups as follows:

        1. Granisetron1 group: women will receive 1mg IV granisetron

        2. Granisetron 0.7 group: women will receive 0.7 mg IV granisetron

        3. Pethidine group: women will receive 25 mg IV pethidine and

        4. Control group: women will receive 2 ml of 0.9% sodium chloride. Throughout the study
           period,shivering scores, core temperature, sensory level and motor block will be
           recorded, heart rate will be measured continuously using an electrocardiogram; blood
           pressure will be determined. If heart rate decreases by more than 20% of the baseline
           atropin will be received and if blood pressure decreases 20% of the baseline ephedrine
           will be received.

      Also, Apgar score at one minute and five minutes will be recorded. At the end patient
      satisfaction will be assessed using Verbal Numeric Scoring system Side effects (bradycardia,
      hypotension, hypothermia, nausea and vomiting, pruritus etc ) will be recorded
      perioperatively in the operating room and postanesthetic care unit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>shivering score</measure>
    <time_frame>180 min (immediately before the block till 90 min after admission to PACU )</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>non invasive blood pressure</measure>
    <time_frame>90 min (immediately before the block till 90 min after the block)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>90 min (immediately before the block till 90 min after the block)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>core temperature</measure>
    <time_frame>180 min (immediately before the block till 90 min after admission to PACU )</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Spinal Induced Shivering</condition>
  <arm_group>
    <arm_group_label>Granisetron 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous granisetron 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Granisetron 0.7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous granisetron 0.7 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pethidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pethidine 25 mg Intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous 0.9% Sodium chloride (2 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>IV granisetron 1 mg before spinal anethesia</description>
    <arm_group_label>Granisetron 1</arm_group_label>
    <other_name>Kytril ampule 3mg/3ml IV (Roche)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>IV granisetron 0.7 mg before spinal anethesia</description>
    <arm_group_label>Granisetron 0.7</arm_group_label>
    <other_name>Kytril ampule 3mg/3ml IV (Roche)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pethidine</intervention_name>
    <description>IV Pethidine 25 mg before spinal anethesia</description>
    <arm_group_label>Pethidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>IV 2 ml 0.9 sodium chloride before spinal anethesia</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9 Sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women at term,

          -  ASA status I or II (American Society of Anesthesiologists) physical status class
             I-II,

          -  low-risk cesarean section,

          -  Scheduled for the spinal anesthesia

        Exclusion Criteria:

          -  Pregnant women in labor

          -  Patients who have the body temperature over 37.3 or less than 37 celsius degree

          -  Known allergies to the study drugs

          -  Contraindication to spinal anesthesia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seham M Moeen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut Univerisity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seham M Moeen, MD</last_name>
    <phone>2413201</phone>
    <phone_ext>088</phone_ext>
    <email>seham.moeen@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hala S Abdel-Ghaffar, MD</last_name>
    <phone>2413201</phone>
    <phone_ext>088</phone_ext>
    <email>hallasaad@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seham Mohamed Moeen Ibrahim</name>
      <address>
        <city>Asyut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seham M Moeen, MD</last_name>
      <phone>2413201</phone>
      <phone_ext>088</phone_ext>
      <email>seham.moeen@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Hala S Abdel-Ghaffar, MD</last_name>
      <phone>2413201</phone>
      <phone_ext>088</phone_ext>
      <email>hallasaad@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 25, 2017</lastchanged_date>
  <firstreceived_date>October 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Seham Mohamed Moeen Ibrahim</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <keyword>Shivering</keyword>
  <keyword>Granisetron</keyword>
  <keyword>Pethidine</keyword>
  <keyword>Spinal</keyword>
  <keyword>Cesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
